Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Ceras-peg
- Development stage
- Preclinical
- Lead developer
- PARAS Biopharma
- Modality
- Recombinant Proteins and Enzymes, Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Administration
- Subcutaneous
01
Overview
Ceras-peg (PB(RA)-2020) is a biosimilar version of certolizumab pegol (Cimzia) being developed by Paras Biopharmaceuticals. It is a PEGylated antibody fragment (Fab) that specifically targets and neutralizes tumor necrosis factor alpha (TNF-alpha), a key pro-inflammatory cytokine involved in the pathogenesis of various inflammatory diseases. The PEGylation of the Fab fragment is designed to extend the drug's half-life in the systemic circulation. Currently in preclinical development, Ceras-peg is primarily being investigated for the treatment of rheumatoid arthritis, aiming to provide a highly similar therapeutic profile to the originator product in terms of safety, efficacy, and quality.
- Brand names
- Ceras-peg
- Other names
- Certolizumab-pegol biosimilarPB-RA-2020PB-RA2020PB-RA 2020
02
Targets
TNFA (Tumor necrosis factor alpha (soluble))
Beyond the preview
Go deeper on Ceras-peg.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Ceras-peg.